Document:

EX-10.11

 Exhibit 10.11 

 

					
	

	  	 TetraPhase Pharmaceuticals, Inc.

480 Arsenal Street, Suite 110
 Watertown, MA
02472
	  	

 December 4, 2007 
 Mr. Guy Macdonald 
 125B Magazine St, 
 Cambridge, MA 02139 
 Dear Guy: 

On behalf of TetraPhase Pharmaceuticals, Inc. (the “Company”), I am very pleased to offer you employment with the Company. The
purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer. 
 1.
Employment. You will be employed, effective January 14, 2008, to serve in the position of President and Chief Executive Officer, reporting to the Board of Directors of the Company (the “Board”), and will have such duties
and responsibilities as are customarily assigned to an officer with such titles and such other duties and responsibilities as may be assigned to you from time to time by the Board. You agree to devote your full business time, best efforts, skill,
knowledge, attention, and energies to the advancement of the Company’s business and interests and to the performance of your duties and responsibilities as an employee of the Company. 

2. Compensation. Your base rate of compensation will be $340,000 on an annual basis, less all applicable federal, state and
local taxes and withholdings, such base salary to be paid in installments in accordance with the Company’s standard payroll practices, which currently provides for payments in monthly installments. Such base salary may be adjusted from time to
time in accordance with normal business practices and in the sole discretion of the Company. 
 3. Bonus. If the
Board approves an annual bonus for fiscal year 2008 or any fiscal year thereafter, you may be eligible for a discretionary award of up to 35% of your annualized base salary in such year. The bonus award, if any, will be based on both individual and
corporate performance and will be determined by the Board in its sole discretion. In order to be eligible for a bonus, if any, you must be an active employee of the Company on the date such bonus is distributed. 

4. Benefits. You shall be eligible to participate in any and all benefit programs that the Company establishes and makes
available to its employees from time to time, provided that you are eligible under (and subject to all provisions of) the plan documents governing those programs. Such benefits currently include: participation in group medical and dental insurance
programs, term life insurance, long-term disability insurance and participation in the Company’s 401(k) plan. The benefits made available by the Company, and the rules, terms, and conditions for participation in such benefit plans, may be
changed by the Company at any time and from time to time without advance notice. 

 5. Stock Incentive Program. 

(a) You will be eligible to participate in the Company’s stock incentive program. The Company will grant to you, effective upon the
first day of your employment, an option to purchase 880,984 shares of the Company’s Common Stock (subject to adjustment for stock splits, stock dividends, combinations, reclassifications and other similar events affecting the Common Stock). In
the event that the Company issues shares of its Series A-2 Convertible Participating Preferred Stock pursuant to Section 1.01(b)(i) of the Stock Purchase Agreement dated as of August 8, 2006 by and among the Company and the Purchasers (as
defined therein) upon the achievement of the Milestone (as defined therein) (such shares being referred to as the “Milestone Shares”), then, subject to the approval of the Board, the Company will grant to you an additional option to
purchase a number of shares of the Company’s Common Stock equal to five percent (5%) of the shares of Common Stock issuable upon conversion of the Milestone Shares as of the date of issuance of the Milestone Shares. 

(b) Each of such stock options (together, the “Options”) will vest (i.e., become exercisable) as to 25% of the shares covered
thereby on the first anniversary of your first day of employment and as to 6.25% of the shares covered thereby every three months thereafter, subject to your continued employment by the Company. The exercise price will be equal to the fair market
value of one share of Common Stock on the date of grant for each of such Options as determined by the Board. Each of such Options will be issued pursuant to the Company’s 2006 Stock Incentive Plan (the “Stock Plan”) and the stock
option agreements covering the Options, which must be executed to effect the grant of any option. Such stock option agreements shall be consistent with the form of option agreement generally used by the Company and the terms of this offer letter.

 (c) Upon the occurrence of a Change in Control Event (as defined below) during your employment with the Company, the vesting
of the Options shall be accelerated in part such that on the date of the Change in Control Event such Options shall vest immediately with respect to 50% of the then unvested shares covered by each of such Options and shall vest with respect to the
balance of the unvested shares in accordance with vesting schedule provided for above (with 50% of the number of shares that would have otherwise vested on each subsequent vesting date in accordance with the vesting schedule above vesting on each
such subsequent vesting date); provided, however, that if (i) you remain employed by the Company or the acquiring or succeeding company for six months following the Change in Control Event, (ii) during the six month period following the
Change in Control Event, your employment with the Company or the acquiring or succeeding company is terminated by the Company or the acquiring or succeeding company without Cause or (iii) during the six month period following the Change in
Control Event, you terminate your employment with the Company or the acquiring or succeeding company as a result of a substantial diminution in your authority and responsibilities from and after the Change in Control Event, then upon the six months
date or the date of such termination, as the case may be, the balance of the unvested shares covered by such Options shall become vested and exercisable in full. For purposes of this offer letter, the definitions of “Change in Control
Event” and “Cause” are set forth on Exhibit A to this offer letter. 
 (d) The Company’s agreement to grant
the Options hereunder is subject to the approval by the Board and the stockholders of the Company of an amendment or amendments to the Stock Plan to increase the number of Shares of Common Stock authorized for issuance thereunder to cover the shares
of Common Stock issuable upon exercise of the Options. 

  
 - 2 -

 (e) In addition to the Options, the Board will review your equity compensation from time to
time and may make such adjustments and grant such additional equity as it shall determine in its sole discretion. 
 6.
At-Will Employment. Your employment with the Company will be on an “at-will” basis, meaning that either you or the Company may terminate the employment relationship at any time, for any reason, with or without cause and with or
without notice. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at-will” nature of your employment may only be changed by a
written agreement signed by you and the Company, which expressly states the intention to modify the at-will nature of your employment. Notwithstanding the foregoing, however, if the Company terminates your employment without Cause, then, in exchange
for and subject to your execution of a separation agreement and release of claims in a form to be provided by, and satisfactory to, counsel for the Company, (a) you will receive as severance pay an amount equal to nine months of your
then-current base salary (subject to all applicable federal, state and local taxes and withholdings, and payable over the nine-month period following such termination in accordance with the Company’s regular payroll practices) and
(b) during such nine-month severance period, the Company will provide you with medical and dental insurance benefits to the extent you were receiving such benefits prior to such termination and to the extent that the Company is able to provide
you with such benefits at a cost to the Company that is not in excess of the cost that the Company was paying for such benefits for you prior to such termination; provided, however, that if you become employed prior to the end of the nine-month
severance period and are eligible to receive medical or dental insurance benefits from your new employer, then the Company shall no longer be required to provide you with such benefits. 

7. Non-Competition, Non-Solicitation and Non-Disclosure Agreement. As a condition of your employment, you will be required
to execute the Company’s Non-Competition, Non-Solicitation and Non-Disclosure Agreement, a copy of which is enclosed with this letter. 
 8. Proof of Legal Right to Work. For purposes of federal immigration law, you will be required to provide the Company with documentary evidence of your identity and eligibility for
employment in the United States. Such documentation must be provided to the Company within three (3) business days of your date of hire, or our employment relationship with you may be terminated. You may need to obtain a work visa in order to
be eligible to work in the United States. If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company. 

9. Company Policies and Procedures. As an employee of the Company, you will be required to comply with all Company policies
and procedures. Violations of the Company’s policies may lead to immediate termination of your employment. Further, the Company’s premises, including all workspaces, furniture, documents, and other tangible materials, and all information
technology resources of the Company (including computers, data and other electronic files, and all internet and email) are subject to oversight and inspection by the Company at any time. Company employees should have no expectation of privacy with
regard to any Company premises, materials, resources, or information. 
 10. Other Agreements and Governing Law.
You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into 

  
 - 3 -

 
employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter. Please note that this offer letter is your formal offer
of employment and supersedes any and all prior or contemporaneous agreements, discussions and understandings, whether written or oral, relating to the subject matter of this letter or your employment with the Company. The resolution of any disputes
under this letter will be governed by Massachusetts law. 
 If this letter correctly sets forth the initial terms under which
you will be employed by the Company, please sign the enclosed duplicate of this letter in the space provided below and return it to my attention at TetraPhase. This offer is effective through December 10, 2007. This offer is contingent on
satisfactory reference checks. 
  

	
	On behalf of TetraPhase Pharmaceuticals, Inc.
	
	 /s/ Lawrence Miller
 Lawrence
Miller

	Chairman

 The foregoing correctly sets forth the terms of my at-will employment by the Company. 

 

							
	 /s/ Guy Macdonald
	 		 	Date:	 	 December 10th 2007

	Guy Macdonald	 		 		 	

  
 - 4 -

 EXHIBIT A 
 Definitions 
 For the purposes of this Offer Letter: 

(1) “Cause” shall mean (a) a good faith finding by the Board that (i) you have failed to substantially perform your
assigned duties for the Company, which failure is not cured within 30 days following written notice from the Company to you specifying the duties not performed, (ii) you have engaged in dishonesty, gross negligence or misconduct or
(iii) you have breached any employment agreement, confidentiality agreement, non-disclosure agreement or other agreement entered into between you and the Company or (b) your conviction of, or the entry of a pleading of guilty or nolo
contendere by you to, any crime involving moral turpitude or any felony. 
 (2) “Change in Control Event” shall
mean: 
 (a) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule
13d-3 promulgated under the Exchange Act) 50% or more of the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”);
provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change in Control Event: (i) any acquisition directly from the Company (excluding an acquisition pursuant to the
exercise, conversion or exchange of any security exercisable for, convertible into or exchangeable for common stock or voting securities of the Company, unless the Person exercising, converting or exchanging such security acquired such security
directly from the Company or an underwriter or agent of the Company), or (ii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company; or 

(b) the consummation of a merger, consolidation, reorganization, recapitalization or statutory share exchange involving the Company or a
sale or other disposition of all or substantially all of the assets of the Company (a “Business Combination”), unless, immediately following such Business Combination all or substantially all of the individuals and entities who were the
beneficial owners of the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the combined voting power of the then-outstanding securities entitled to vote
generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or
substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership of the Outstanding Company Voting Securities immediately prior to such Business Combination.

  
 - 5 -

 December 19, 2008 
 Guy Macdonald 
 125B Magazine Street 
 Cambridge, MA 02139 
 Dear Guy: 
 To ensure compliance with Section 409A of the Internal Revenue Code of 1986, as amended, TetraPhase Pharmaceuticals, Inc. (the “Company”) and you hereby agree to amend the offer
letter dated December 4, 2007 by and between the Company and you (the “Offer Letter”) as follows: 
  

	1.	It is agreed that Section 3 of the Offer Letter is amended by inserting the following at the end of the paragraph: 

“Any bonus payable to you under this letter will be paid between January 1 and March 15 of the calendar year following the
calendar year in which such bonus is earned and approved by the Board.” 
  

	2.	It is further agreed that the third sentence in Section 6 of the Offer Letter is amended and restated in its entirety as follows 

“Notwithstanding the foregoing, however, if the Company terminates your employment without Cause, then, in exchange for and subject
to your execution and non-revocation of a separation agreement and release of claims within 60 days after your termination of employment in a form to be provided by, and satisfactory to, counsel for the Company, (a) you will receive as
severance pay an amount equal to nine months of your then-current base salary (subject to all applicable federal, state and local taxes and withholdings, and payable in accordance with the Company’s regular payroll practices) and
(b) during such nine-month severance period, the Company will provide you with medical and dental insurance benefits to the extent you were receiving such benefits prior to such termination and to the extent that the Company is able to provide
you with such benefits at a cost to the Company that is not in excess of the cost that the Company was paying for such benefits for you prior to such termination; provided, however, that if you become employed prior to the end of the nine-month
severance period and are eligible to receive medical or dental insurance benefits from your new employer, then the Company shall no longer be required to provide you with such benefits. The nine-month severance period will commence with the first
payroll date after the revocation period ends, provided that if the 60th day following your date of termination falls in the calendar year after the year in which your employment terminates, the payment will be made no earlier than the
first day of such later calendar year.” 

	3.	It is further agreed that the following language will be inserted as Section 11 of the Offer Letter: 

“11. Section 409A of the Code. Subject to the provisions in this Section 11, any severance payments or
benefits under this letter will begin only upon the date of your “separation from service” (determined as set forth below) which occurs on or after the date of termination of your employment. The following rules shall apply with respect to
distribution of the payments and benefits, if any, to be provided to you under this letter. 
 (a) It is intended
that each installment of the severance payments and benefits provided under this letter shall be treated as a separate “payment” for purposes of Section 409A of the Code and the guidance issued thereunder (“Section 409A”).
Neither you nor the Company will have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A. 

(b) The determination of whether and when your separation from service from the Company has occurred shall be made and in
a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this paragraph, “Company” shall include all persons with whom the Company would be considered a
single employer under Section 414(b) and 414(c) of the Code. 
 (c) All reimbursements and in-kind benefits
provided under this letter shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements
that (i) any reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified in your offer letter), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the
expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the
right to reimbursement is not subject to set off or liquidation or exchange for any other benefit. 
 (d)
Notwithstanding anything herein to the contrary, the Company shall have no liability to you or to any other person if the payments and benefits provided in this letter that are intended to be exempt from or compliant with Section 409A are not
so exempt or compliant.” 

  
 -2-

 
	
	On behalf of TetraPhase Pharmaceuticals, Inc.
	
	/s/ Lawrence Miller
	Lawrence Miller
	Chairman

 By execution of this letter, you hereby agree to the foregoing amendment of the Offer Letter and reaffirm your
obligations under the Offer Letter. 
  

							
	 /s/ Guy Macdonald
	 		 	Date:	 	 12/23/08

 [Add Confidentiality agreement] 

  
 -3-EX-10.12

 Exhibit 10.12 
 TETRAPHASE PHARMACEUTICALS, INC. 
 August 10, 2006 

David Lubner 
 4 Michael Circle 

Southborough MA 01772 
 Dear David: 

On behalf of Tetraphase Pharmaceuticals, Inc. (the “Company”), I am very pleased to offer you employment with the Company. The
purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer. 
 1.
Employment. You will be employed, effective September 4, 2006, to serve in the position of Senior Vice President and Chief Operating Officer, will report to the principal executive officer of the Company [and the Board of Directors]
and will have such duties and responsibilities as are customarily assigned to an officer with such titles and such other duties and responsibilities as may be assigned to you by the principal executive officer of the Company and the Board of
Directors. You agree to devote approximately 50% of your full business time (approximately two and one-half days per week) and your best efforts, skill, knowledge, attention and energies to the advancement of the Company’s business and
interests and to the performance of your duties and responsibilities as an employee of the Company. 
 2.
Compensation. Your base rate of compensation will be $140,000 on an annual basis, less all applicable federal, state and local taxes and withholdings, such base salary to be paid in installments in accordance with the Company’s
standard payroll practices. Such base salary may be adjusted from time to time in accordance with normal business practices and in the sole discretion of the Company. 
 3. Bonus. If the Board of Directors approves an annual bonus for fiscal year 2006 or any fiscal year thereafter, you may be eligible for a discretionary award of up to 20% of your annualized
base salary in such year. The bonus award, if any, will be based on both individual and corporate performance and will be determined by the Board of Directors in its sole discretion. In order to be eligible for a fiscal year bonus, if any, you must
be an active employee of the Company on the date such bonus is distributed. 
 4. Benefits. You will be eligible
to participate in any and all bonus and benefit programs that the Company establishes and makes available to its employees from time to time, provided that you are eligible under (and subject to all provisions of) the plan documents governing those
programs. Such benefits may include: participation in group medical and dental insurance programs, term life insurance, long-term disability insurance and participation in the Company’s 401(k) plan. The benefits made available by the Company,
and the rules, terms, and conditions for participation in such benefit plans may be changed by the Company at any time and from time to time without advance notice. 
 Tetraphase Pharmaceuticals, Inc. Confidential 

 5. Stock Incentive Program. You will be eligible to participate in the
Company’s stock incentive program. Subject to approval by the Company’s Board of Directors, the Company will grant to you an option to purchase (or an award of restricted stock for the purchase of) 280,000 shares of the Company’s
Common Stock (subject to adjustment for stock splits, combinations, or other recapitalizations) which will vest (i.e., become exercisable in the case of options) on the same terms and in the same manner as the restricted stock granted to you under
the Restricted Stock Agreement dated August 3, 2006, subject to your continued employment by the Company. The option exercise price (or restricted stock purchase price) will equal the fair market value of one share of Common Stock on the date
of grant of the option (or restricted stock award) as determined by the Company’s Board of Directors. The option (or restricted stock award) will be issued pursuant to the Company’s 2006 Stock Incentive Plan and the stock option agreement
covering the option (or the restricted stock agreement covering the restricted stock award), which must be executed to effect the grant of any option (or restricted stock award). 

6. At-Will Employment. Your employment with the Company will be on an “at-will” basis, meaning that either you or
the Company may terminate the employment relationship at any time, for any reason, with or without cause and with or without notice. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and
procedures, may change from time to time, the “at-will” nature of your employment may only be changed by a written agreement signed by you and the principal executive officer of the Company, which expressly states the intention to modify
the at-will nature of your employment. Notwithstanding the foregoing, however, should the Company terminate your employment without “cause,” as that term is defined in this paragraph, you will receive as severance pay an amount equal to
three (3) months of your then-current base salary (subject to all applicable federal, state and local taxes and withholdings, and payable over the three-month period following such termination in accordance with the Company’s regular
payroll practices) in exchange for your execution of a separation agreement and release of claims in a form to be provided by, and satisfactory to, counsel for the Company. For purposes hereof “cause” shall mean (a) a good faith
finding by the Board of Directors of the Company that (i) you have failed to substantially perform your assigned duties for the Company, which failure is not cured within 20 days following written notice from the Company to you specifying the
duties not performed, (ii) you have engaged in dishonesty, gross negligence or misconduct or (iii) you have breached any employment agreement, confidentiality agreement, non-disclosure agreement or other agreement entered into between you
and the Company or (b) your conviction of, or the entry of a pleading of guilty or nolo contendere by you to, any crime involving moral turpitude or any felony. 
 7. Non-Competition, Non-Solicitation and Non-Disclosure Agreement. As a condition of your employment, you will be required to execute the Company’s Non-Competition, Non-Solicitation and
Non-Disclosure Agreement, a copy of which is enclosed with this letter. 
 8. Proof of Legal Right to Work. For
purposes of federal immigration law, you will be required to provide the Company with documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to the

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 - 2 - 

 
Company within three (3) business days of your date of hire, or our employment relationship with you may be terminated. You may need to obtain a work visa in order to be eligible to work in
the United States. If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company. 
 9. Company Policies and Procedures. As an employee of the Company, you will be required to comply with all Company policies and procedures. Violations of the Company’s policies may lead
to immediate termination of your employment. Further, the Company’s premises, including all workspaces, furniture, documents, and other tangible materials, and all information technology resources of the Company (including computers, data and
other electronic files, and all internet and email) are subject to oversight and inspection by the Company at any time. Company employees should have no expectation of privacy with regard to any Company premises, materials, resources, or
information. 
 10. Other Agreements and Governing Law. You represent that you are not bound by any employment
contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter. Please note that this
offer letter is your formal offer of employment and supersedes any and all prior or contemporaneous agreements, discussions and understandings, whether written or oral, relating to the subject matter of this letter or your employment with the
Company. The resolution of any disputes under this letter will be governed by Massachusetts law. 
 If this letter correctly
sets forth the initial terms under which you will be employed by the Company, please sign the enclosed duplicate of this letter in the space provided below and return it to me in the attached envelope along with the signed Non-Competition,
Non-Solicitation and Non-Disclosure Agreement. If you do not accept this offer by August 17, 2006, this offer will be revoked. This offer is contingent on satisfactory reference checks.  

 

	
	On behalf of Tetraphase Pharmaceuticals, Inc.
	
	 /s/ Lawrence Miller 
 Lawrence Miller
 President

 The foregoing correctly sets forth the terms of my employment by Tetraphase Pharmaceuticals, Inc. 

 

							
	 /s/ David Lubner
	 		 	Date:	 	 8-14-06

	David Lubner	 		 		 	

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 - 3 - 

 December 19, 2008 
 Mr. David Lubner 
 4 Michael Circle 
 Southborough MA 01772 
 Dear David: 
 To ensure compliance with Section 409A of the Internal Revenue Code of 1986, as amended, TetraPhase Pharmaceuticals, Inc. (the “Company”) and you hereby agree to amend the offer
letter dated August 10, 2006 by and between the Company and you (the “Offer Letter”) as follows: 
  

	1.	It is agreed that Section 3 of the Offer Letter is amended by inserting the following at the end of the paragraph: 

“Any bonus payable to you under this letter will be paid between January 1 and March 15 of the calendar year following the
calendar year in which such bonus is earned and approved by the Board.” 
  

	2.	It is further agreed that the third sentence in Section 6 of the Offer Letter is amended and restated in its entirety as follows: 

“Notwithstanding the foregoing, however, should the Company terminate your employment without “cause,” as that term is
defined in this paragraph, you will receive as severance pay an amount equal to three (3) months of your then-current base salary (subject to all applicable federal, state and local taxes and withholdings, and payable in accordance with the
Company’s regular payroll practices) in exchange for your execution and non-revocation of a separation agreement and release of claims within sixty (60) days after your termination of employment in a form to be provided by, and
satisfactory to, counsel for the Company. The three (3) month severance period will commence with the first payroll date after the revocation period ends, provided that if the 60th day following your date of termination falls in the
calendar year after the year in which your employment terminates, the payment will be made no earlier than the first day of such later calendar year.” 
  

	3.	It is further agreed that the following language will be inserted as Section 11 of the Offer Letter: 

“11. Section 409A of the Code. Subject to the provisions in this Section 11, any severance payments or
benefits under this letter will begin only upon the date of your “separation from service” (determined as set forth below) which occurs on or after the date of termination of your employment. The following rules shall apply with respect to
distribution of the payments and benefits, if any, to be provided to you under this letter. 

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 - 4 - 

 (a) It is intended that each installment of the severance payments and
benefits provided under this letter shall be treated as a separate “payment” for purposes of Section 409A of the Code and the guidance issued thereunder (“Section 409A”). Neither you nor the Company will have the right to
accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A. 
 (b) The determination of whether and when your separation from service from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury
Regulation Section 1.409A-1(h). Solely for purposes of this paragraph, “Company” shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code. 

(c) All reimbursements and in-kind benefits provided under this letter shall be made or provided in accordance with the
requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during your
lifetime (or during a shorter period of time specified in your offer letter), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year,
(iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or
exchange for any other benefit. 
 (d) Notwithstanding anything herein to the contrary, the Company shall have no
liability to you or to any other person if the payments and benefits provided in this letter that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.” 

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 - 5 - 

 
	
	On behalf of TetraPhase Pharmaceuticals, Inc.
	
	/s/ Lawrence Miller
	Lawrence Miller
	Chairman

 By execution of this letter, you hereby agree to the foregoing amendment of the Offer Letter and reaffirm your
obligations under the Offer Letter. 
  

							
	 /s/ David Lubner
	 		 	Date:	 	 12/19/08

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 - 6 - 

  
 

 
 June 29, 2012 
 Mr. David Lubner 
 4 Michael Circle 
 Southborough, MA 01772 
 Dear David: 
 As you are aware, Tetraphase Pharmaceuticals, Inc. (the “Company”) has agreed to increase your severance benefits under the offer letter dated August 10, 2006, as amended
December 19, 2008, by and between the Company and you (the “Offer Letter”). In order to effect such increase, the Company hereby agrees that the third sentence in Section 6 of the Offer Letter be amended and restated in
its entirety as follows: 
 “Notwithstanding the foregoing, however, should the Company terminate your employment without
“cause,” as that term is defined in this paragraph, (a) you will receive as severance pay an amount equal to six (6) months of your then-current base salary (subject to all applicable federal, state and local taxes and
withholdings, and payable in accordance with the Company’s regular payroll practices) and (b) during such six-month severance period, the Company will provide you with medical and dental insurance benefits to the extent you were receiving
such benefits prior to such termination and to the extent that the Company is able to provide you with such benefits at a cost to the Company that is not in excess of the cost that the Company was paying for such benefits for you prior to such
termination; provided, however, that if you become employed prior to the end of the six-month severance period and are eligible to receive medical or dental insurance benefits from your new employer, then the Company shall no longer be required to
provide you with such benefits, each of the benefits provided above in clauses (a) and (b) to be provided in exchange for your execution of a separation agreement and release of claims in a form to be provided by, and satisfactory to,
counsel for the Company. The six (6) month severance period will commence with the first payroll date after the revocation period ends, provided that if the 60th day following your date of termination falls in the calendar year after the year
in which your employment terminates, the payment will be made no earlier than the first day of such later calendar year.” 

Tetraphase Pharmaceuticals, Inc. Confidential 

 Please confirm your agreement to the foregoing by signing this letter in the place indicated
below. 
  

	
	Tetraphase Pharmaceuticals, Inc.
	
	/s/ Guy Macdonald
	 Guy Macdonald
 President and
Chief Executive Officer

 By execution of this letter, you hereby agree to the foregoing amendment of the Offer Letter and reaffirm your
obligations under the Offer Letter. 
  

							
	 /s/ David Lubner
	 		 	Date:	 	 6/29/12

	David Lubner	 		 		 	

  
 Tetraphase
Pharmaceuticals, Inc. Confidential 
 - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]